T
Thomas Harding
Researcher at United States Department of the Army
Publications - 195
Citations - 10183
Thomas Harding is an academic researcher from United States Department of the Army. The author has contributed to research in topics: Cancer & PARP inhibitor. The author has an hindex of 37, co-authored 184 publications receiving 8509 citations. Previous affiliations of Thomas Harding include University of Canterbury & Research Triangle Park.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher,Kevin K. Lin,Amit M. Oza,Clare L. Scott,Heidi Giordano,James Sun,Gottfried E. Konecny,Robert L. Coleman,Anna V. Tinker,David M. O'Malley,Rebecca Kristeleit,Ling Ma,Katherine M. Bell-McGuinn,James D. Brenton,Janiel M. Cragun,Ana Oaknin,Isabelle Ray-Coquard,Maria I. Harrell,Elaina Mann,Scott H. Kaufmann,Anne Floquet,Alexandra Leary,Thomas Harding,Sandra Goble,Lara Maloney,Jeff Isaacson,Andrew R. Allen,Lindsey Rolfe,Roman Yelensky,Mitch Raponi,Iain A. McNeish +30 more
TL;DR: The ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor, was assessed in ARIEL2, an international, multicentre, two-part, phase 2, open-label study.
Journal ArticleDOI
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta,Barry R. Davies,Ian Hickson,Thomas Harding,Sabina Cosulich,Susan E. Critchlow,John Vincent,Rebecca Ellston,Darren Jones,Patrizia Sini,Dominic I. James,Zoe Howard,Phillippa Dudley,Gareth M. Hughes,Lisa Smith,Sharon Maguire,Marc Geoffrey Hummersone,Karine Malagu,Keith Allan Menear,Richard O. Jenkins,Matt Jacobsen,Graeme C. M. Smith,Sylvie Guichard,Martin Pass +23 more
TL;DR: AZD8055 is described, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L, which results in significant growth inhibition and/or regression in xenografts, representing a broad range of human tumor types.
Journal ArticleDOI
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Annette O Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jing Sun,Kwangho Lee,Aleksander Dubrovskiy,Matthew T. Labenski,Zhendong Zhu,Zhigang Wang,Michael Sheets,Thia St Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,M. Nacht,Russell C. Petter,William F. Westlin,Kevin K. Lin,Sarah Jaw-Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoe Weaver,William Pao,Juswinder Singh,Andrew Simmons,Thomas Harding,Andrew E. Allen +29 more
TL;DR: CO-1686 is the fi rst drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR.
Journal ArticleDOI
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon,Andrew Simmons,Alexander F. Lovejoy,Mohammad Shahrokh Esfahani,Aaron M. Newman,Henry J. Haringsma,David M. Kurtz,Henning Stehr,Florian Scherer,Chris Karlovich,Thomas Harding,Kathleen A. Durkin,Gregory A. Otterson,W. Thomas Purcell,D. Ross Camidge,Jonathan W. Goldman,Lecia V. Sequist,Zofia Piotrowska,Heather A. Wakelee,Joel W. Neal,Ash A. Alizadeh,Maximilian Diehn +21 more
TL;DR: In this article, the authors employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.